Hydralazine Injection Rx
Generic Name and Formulations:
Hydralazine (as HCl) 20mg/mL; IM or IV inj; contains parabens.
Various generic manufacturers
Indications for Hydralazine Injection:
Severe essential hypertension when oral therapy not feasible or there is an urgent need to lower blood pressure.
Monitor BP closely. 20–40mg; repeat as needed. Advanced renal damage: reduce dose.
Not recommended; doses of 1.7–3.5mg/kg per day in 4–6 divided doses have been used.
Coronary artery disease. Mitral valve disease.
Suspected coronary artery disease. Cerebrovascular accidents. Aortic aneurysm. Increased intracranial pressure. Renal disease. Treat paresthesias and/or numbness with pyridoxine. Discontinue if blood dyscrasias occur. Obtain CBC and ANA titer periodically; consider discontinuing if SLE occurs. Surgery. Pregnancy (Cat.C). Nursing mothers.
Caution with MAOIs. Profound hypotension with potent parenteral antihypertensives (eg, diazoxide). Antagonized by NSAIDs. May block epinephrine.
Headache, anorexia, GI disturbances, palpitations, edema, flushing, nasal congestion, lacrimation, rash, tachycardia, angina, orthostatic hypotension, blood dyscrasias, peripheral neuritis, SLE.
Formerly known under the brand names Apresoline (inj, tabs); Dralzine (tabs).
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|